Procainamide

IUPAC: 4 -amino-N -(2- diethylaminoethyl) -benzamide

• C13H21N3O2 ( procainamide )
• C13H21N3O2 HCl ( procainamide · hydrochloride)

• 51-06-9 ( procainamide )
• 614-39-1 ( procainamide hydrochloride)

C01BA02

Antiarrhythmic

• 235.33 g · mol -1 ( procainamide )
• 271.79 g.mol -1 ( · procainamide hydrochloride)

• 46-48 ° C
• 165-169 ° C ( procainamide hydrochloride)

210-215 ° C ( 267 Pa )

9.32

Water: 5050 mg · l-1 at 25 ° C

Hydrochloride

Attention

1950 mg · kg -1 ( LD50, rat, oral)

Template: Infobox chemical / molecular formula search available

Procainamide ( in Europe except commercial ) is structurally related to procaine. It is an antiarrhythmic agent of the group of sodium channel blockers. Thus, it belongs to the class Ia antiarrhythmic drugs after the Vaughan / Williams classification. Procainamide is used as Reserveantiarrhythmikum in treatment- resistant ventricular arrhythmias and supraventricular arrhythmias in pre-excitation.

Pharmacokinetics

Procainamide has a short plasma half-life of 2 to 4 hours and has a bioavailability of approximately 80%. Since procainamide is excreted via the kidneys, dosage adjustments in renal impairment should be considered.

Pharmacodynamics

It has a weaker anticholinergic action as quinidine. Procainamide may result in long-term therapy for the induction of antinuklären antibodies ( systemic lupus erythematosus ), in this case, it should be promptly discontinued. Furthermore, it is possible that the treatment can occur with procainamide urticaria, fever and agranulocytosis.